Found 55 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
docetaxel plus epirubicin, and docetaxel plus epirubicin plus cyclophosphamide as neoadjuvant chemotherapy for operable premenopausal breast cancer patients, and also to compare the outcomes associated with
- 0 views
- 21 Jan, 2021
- 7 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin
- 90 views
- 16 Apr, 2020
- 27 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of
- 2 views
- 15 Mar, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Regimens Comparison for Breast Cancers of Positive Lymph Nodes
To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes
- 6 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
1000s of participants
-
An interventional trial
-
For all genders
-
Oncology
-
Currently Recruiting
Combination Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating esophageal cancer. PURPOSE: Randomized phase …
- 31 views
- 07 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …
- 33 views
- 07 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
This is a multicenter, international, double-blind randomized Phase III study to evaluate the pathological complete response (pCR) according to Chevalier classification between Fulvestrant and the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the OncotypeDX …
- 161 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Both TC (docetaxel/carboplatin) and EC followed by T (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been
- 4 views
- 08 Nov, 2020
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Patients with ER+/HER2 breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in ER+/HER2 breast cancer patients.
- 8 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most
- 0 views
- 08 Nov, 2020
- 1 location